Esteva FJ et al. |
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? |
2015 |
Am Soc Clin Oncol Educ Book |
pmid:25993162
|
Hamblett KJ et al. |
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. |
2015 |
Mol. Cancer Ther. |
pmid:25931519
|
Ab O et al. |
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. |
2015 |
Mol. Cancer Ther. |
pmid:25904506
|
Weiler D et al. |
Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. |
2015 |
J Thorac Oncol |
pmid:25789838
|
Krop IE et al. |
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. |
2015 |
J. Clin. Oncol. |
pmid:25713436
|
Marcoux J et al. |
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. |
2015 |
Protein Sci. |
pmid:25694334
|
Goldmacher VS et al. |
High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. |
2015 |
PLoS ONE |
pmid:25671541
|
Nicoletti R et al. |
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. |
2015 |
Clin. Exp. Metastasis |
pmid:25398397
|
Uppal H et al. |
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). |
2015 |
Clin. Cancer Res. |
pmid:25370470
|
Krop IE et al. |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. |
2015 |
Ann. Oncol. |
pmid:25355722
|
Eisenstein M |
Medicine: Eyes on the target. |
2015 |
Nature |
pmid:26580159
|
Widdison WC et al. |
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing. |
2015 |
Bioconjug. Chem. |
pmid:26355774
|
Cosmai L et al. |
Renal toxicity of anticancer agents targeting HER2 and EGFR. |
2015 |
J. Nephrol. |
pmid:26341657
|
Bartsch R et al. |
Activity of T-DM1 in Her2-positive breast cancer brain metastases. |
2015 |
Clin. Exp. Metastasis |
pmid:26303828
|
Michel LL et al. |
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. |
2015 |
Anticancer Res. |
pmid:26254411
|
Piwko C et al. |
Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. |
2015 |
Clin Drug Investig |
pmid:26123628
|
Hayashi T et al. |
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. |
2015 |
J. Urol. |
pmid:26047983
|
Shen BQ et al. |
Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. |
2015 |
Drug Metab Lett |
pmid:26031461
|
Kan S et al. |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. |
2015 |
Oncol. Rep. |
pmid:25976081
|
Dholaria B and Srinivasan S |
T-DM1-related carotenoderma and hand-foot syndrome. |
2015 |
Lancet |
pmid:25933279
|
Carneiro BA et al. |
Emerging therapeutic targets in bladder cancer. |
2015 |
Cancer Treat. Rev. |
pmid:25498841
|
Mang Y et al. |
Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immunocompetent mice. |
2015 |
Int. Immunopharmacol. |
pmid:25467246
|
Kalsi R et al. |
Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. |
2015 |
Clin. Breast Cancer |
pmid:25454740
|
Sibaud V et al. |
T-DM1-related telangiectasias: a potential role in secondary bleeding events. |
2015 |
Ann. Oncol. |
pmid:25403586
|
Yamamoto H et al. |
Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. |
2015 |
Jpn. J. Clin. Oncol. |
pmid:25332421
|
Whiteman KR et al. |
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. |
2014 Mar-Apr |
MAbs |
pmid:24492307
|
Tanz R et al. |
[Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer]. |
2014 Jul-Aug |
Bull Cancer |
pmid:25091656
|
Panowski S et al. |
Site-specific antibody drug conjugates for cancer therapy. |
2014 Jan-Feb |
MAbs |
pmid:24423619
|
Beck A and Reichert JM |
Antibody-drug conjugates: present and future. |
2014 Jan-Feb |
MAbs |
pmid:24423577
|
Lieberman P and Castells M |
Desensitization to chemotherapeutic agents. |
2014 Jan-Feb |
J Allergy Clin Immunol Pract |
pmid:24565784
|
Leal M et al. |
Antibody-drug conjugates: an emerging modality for the treatment of cancer. |
2014 |
Ann. N. Y. Acad. Sci. |
pmid:25123209
|
Perrino E et al. |
Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. |
2014 |
Cancer Res. |
pmid:24520075
|
Bender B et al. |
A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. |
2014 |
AAPS J |
pmid:24917179
|
Cretella D et al. |
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. |
2014 |
Mol. Cancer |
pmid:24898067
|
English DP et al. |
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. |
2014 |
Cancer Med |
pmid:24890382
|
Perez EA et al. |
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. |
2014 |
Breast Cancer Res. |
pmid:24887458
|
Barok M et al. |
Trastuzumab emtansine: mechanisms of action and drug resistance. |
2014 |
Breast Cancer Res. |
pmid:24887180
|
Tripathy D et al. |
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. |
2014 |
BMC Cancer |
pmid:24885258
|
Amiri-Kordestani L et al. |
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. |
2014 |
Clin. Cancer Res. |
pmid:24879797
|
Stinchcombe TE |
Novel formulations and new mechanisms of delivering chemotherapy. |
2014 |
Am Soc Clin Oncol Educ Book |
pmid:24857128
|
Giordano SH et al. |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. |
2014 |
J. Clin. Oncol. |
pmid:24799465
|
Corrigan PA et al. |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. |
2014 |
Ann Pharmacother |
pmid:25082874
|
Diéras V et al. |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. |
2014 |
J. Clin. Oncol. |
pmid:25024070
|
Yu L et al. |
Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model. |
2014 |
Int. J. Gynecol. Cancer |
pmid:24987913
|
Lambert JM and Chari RV |
Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. |
2014 |
J. Med. Chem. |
pmid:24967516
|
Sibaud V et al. |
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. |
2014 |
Breast Cancer Res. Treat. |
pmid:24929675
|
Martin K et al. |
The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. |
2014 |
Cancer Immunol. Immunother. |
pmid:24906866
|
Kim MT et al. |
Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. |
2014 |
Bioconjug. Chem. |
pmid:24873191
|
Kolarich AR et al. |
Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. |
2014 |
Acta Oncol |
pmid:24834794
|
Boku N |
HER2-positive gastric cancer. |
2014 |
Gastric Cancer |
pmid:23563986
|